广东永顺生物制药股份有限公司 募集资金年度存放与使用情况鉴证报告 天健会计师事务所 Pan-China Certified Public Accountants 目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告 …………… 第 3—7 页 三、附件………………………………………………………… 第 8—11 页 (一) 本所营业执照复印件………………………………………第 8 页 (二) 本所执业证书复印件………………………………………第 9 页 (三) 本所签字注册会计师执业证书复印件………………第 10—11 页 募集资金年度存放与使用情况鉴证报告 天健审〔2023〕2-188 号 广东永顺生物制药股份有限公司全体股东： 我们鉴证了后附的广东永顺生物制药股份有限公司（以下简称永顺生物公司） 管理层编制的 2022 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供永顺生物公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为永顺生物公司年度报告的必备文件，随同其他文件 ...

广东永顺生物制药股份有限公司 关于治理专项自查及规范活动相关情况的报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 根据公司治理专项自查及规范活动的相关要求，广东永顺生物制药股份有限公司 （以下简称"公司"或"上市公司"）结合《公司法》《证券法》《北京证券交易所股票 上市规则（试行）》等法律法规及《公司章程》等内部规章制度，按照公司治理有关文 件的精神，严格对公司治理情况进行了自查。现将自查情况、自我规范情况报告如下： 一、 公司基本情况 公司属性为民营企业。 公司不存在实际控制人。 公司不存在控股股东。 公司控制的其他企业不存在接受他人表决权委托的情况。公司控制的其他企业不存 在与他人签署一致行动协议的情况。 证券代码：839729 证券简称：永顺生物 公告编号：2023-033 公司不存在控股子公司持有公司股份的情形。 二、 内部制度建设情况 公司内部制度建设情况如下： | 事项 | 是或否 | | --- | --- | | 对照《北京证券交易所股票上市规则（试行）》等业务规则完 | 是 | | ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-019 广东永顺生物制药股份有限公司 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 4 月 19 日 2.会议召开地点：广东省现代农业集团有限公司二楼会议室 3.会议召开方式：现场表决 4.发出董事会会议通知的时间和方式：2023 年 4 月 7 日以书面方式发出 5.会议主持人：董事长谭德明 6.会议列席人员：公司监事、公司高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的参与表决董事人数、召集、召开程序和议事内容均符合《公司法》、 《公司章程》及相关法律法规的规定，所作决议合法有效。 （二）会议出席情况 会议应出席董事 8 人，出席和授权出席董事 8 人。 二、议案审议情况 （一）审议通过《关于 2022 年度董事会工作报告的议案》 1.议案内容： 根据《公司章程》相关规定，针对公司董事会 2022 年度的工作情 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-026 广东永顺生物制药股份有限公司 关于向银行申请授信额度的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、申请授信的基本情况 广东永顺生物制药股份有限公司（以下简称"公司"）拟向招商银行股份有 限公司广州分行申请综合授信额度人民币 1 亿元。向中国建设银行股份有限公司 广州天河支行申请综合授信额度人民币 5000 万元。向上海浦东发展银行股份有 限公司广州分行申请综合授信额度人民币 5000 万元。向中国农业银行股份有限 公司广州开发区分行申请综合授信额度人民币 1 亿元。向中国工商银行股份有限 公司广州高新技术开发区支行申请综合授信额度人民币 5000 万元。向中信银行 股份有限公司广州宝岗大道支行申请综合授信额度人民币 1 亿元。向中国民生银 行股份有限公司广州分行申请综合授信额度人民币 5000 万元。向交通银行股份 有限公司广州越秀支行申请综合授信额度人民币 1 亿元。以上授信额度合计人民 币 6 亿元。授信及授权期限 ...

Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 20,894,809.49, representing a growth of 20.58% year-on-year[9] - Operating revenue for the first quarter of 2023 was CNY 81,091,529.35, up 3.07% from the same period last year[9] - Total operating revenue for Q1 2023 reached ¥81,091,529.35, an increase of 3.6% compared to ¥78,677,625.48 in Q1 2022[58] - Total profit reached CNY 23,799,155.91, up from CNY 19,841,045.10, indicating a growth of approximately 19.7%[63] - Operating profit slightly decreased to CNY 18,864,589.14 from CNY 19,833,123.92, a decline of about 4.9%[63] - Basic and diluted earnings per share for Q1 2023 were both ¥0.08, up from ¥0.06 in Q1 2022[60] - The company reported a significant increase in interest income to CNY 1,687,597.44 from CNY 1,188,495.23, representing a growth of approximately 42%[63] - Net profit rose to CNY 20,889,136.99, compared to CNY 17,322,251.00, marking an increase of about 20.5% year-over-year[64] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net outflow of CNY 14,410,166.78, a decrease of 9283.03% compared to the previous year[13] - Cash flow from investment activities showed a net outflow of CNY 50,994,104.00, a significant increase of 539.85% compared to the previous year[13] - The net cash flow from operating activities was -14,415,846.86, a significant decrease compared to 149,774.03 from the previous period, indicating a decline in operational efficiency[68] - The total cash outflow from operating activities was 76,338,631.09, which is an increase from 61,643,415.40 in the previous period, indicating rising operational costs[68] - The company faced a net cash outflow of 50,994,104.00 from investing activities, highlighting a focus on capital expenditures despite the negative cash flow[68] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 881,274,401.64, an increase of 1.42% compared to the end of the previous year[9] - The total liabilities to assets ratio remained stable at 19.30% for both the parent and consolidated entities[9] - Total liabilities decreased to ¥170,113,880.59 from ¥172,771,172.59, a reduction of approximately 1.53%[52] - Total equity attributable to shareholders rose to ¥711,160,521.05 from ¥696,141,073.57, an increase of approximately 2.16%[52] - Total non-current assets decreased to ¥244,289,161.03 from ¥251,674,448.53, a decline of about 2.94%[51] - Cash and cash equivalents decreased to ¥257,183,751.02 from ¥293,867,101.54, a decline of about 12.5%[50] Shareholder Information - The total number of shareholders as of the report date was 3,426[17] - The company reported a total share repurchase of 3,055,980 shares, accounting for 1.12% of the total share capital, with a total expenditure of approximately ¥24.60 million, representing 57.09% of the planned repurchase fund limit[31] - The company has a significant shareholder structure, with the largest shareholder holding 39.06% and the second-largest holding 19.71%[22] - The company has successfully implemented its share repurchase plan, achieving 84.89% of the planned repurchase quantity[31] Legal and Compliance - The company is involved in two non-significant lawsuits with a total claim amount of ¥4.98 million, currently in the execution phase[27] - The company has not reported any significant external guarantees or loans during the reporting period[26] - The company has no reported cases of asset seizure, freezing, or other significant legal issues during the reporting period[26] - Major shareholders have signed commitments to avoid competition, which were fulfilled without any violations during the reporting period[33] - Commitments to avoid fund occupation by major shareholders were adhered to without any breaches in the reporting period[34] - The company has maintained compliance with commitments to regulate related party transactions, with no violations reported[35] Research and Development - Research and development expenses for Q1 2023 were ¥6,647,428.05, up from ¥5,504,816.75 in Q1 2022, indicating an increase of 20.7%[59] - R&D expenses increased to CNY 6,647,428.05 from CNY 5,504,816.75, reflecting a growth of approximately 20.7%[63]

广东永顺生物制药股份有限公司 章程 第一章 总则 | 序号 | 发起人名称 | 持股数（万股） | 持股比例 | | --- | --- | --- | --- | | 1 | 广东省现代农业集团有限公司 | 3500.00 | 50.00% | | 2 | 广东省农科集团有限公司 | 2029.20 | 28.99% | | 3 | 广东省农业科学院动物卫生研究所 | 880.00 | 12.57% | | 4 | 蔡建平 | 106.42 | 1.52% | | 5 | 谢丽君 | 56.00 | 0.80% | | 6 | 谢雯 | 54.00 | 0.77% | | 7 | 张健騑 | 49.50 | 0.71% | | 8 | 杨傲冰 | 40.00 | 0.57% | | 9 | 张毓金 | 35.00 | 0.50% | | 10 | 吕殿红 | 31.50 | 0.45% | | 11 | 林克义 | 30.00 | 0.43% | 3 第一条 为维护广东永顺生物制药股份有限公司（以下简称"公司"）、股东和债权 人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司 法》（以下简称"《公 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-034 广东永顺生物制药股份有限公司 关于召开 2022 年年度股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东大会届次 本次会议为 2022 年年度股东大会。 （二）召集人 本次股东大会的召集人为董事会。 （三）会议召开的合法性、合规性 本次股东大会的召开符合《公司法》等法律、规范性文件和《公司章程》的 相关规定，会议召开合法合规。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 同一表决权只能选择现场投票和网络投票方式中的一种。同一表决权出现 重复表决的以第一次投票结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2023 年 5 月 16 日 14：30。 2. 本公司董事、监事、高级管理人员。 3. 本公司聘请的律师。 广东君信经纶君厚律师事务所律师。 （七）会议地点 2、网络投票起止时间：2023 年 5 月 15 日 15:00—20 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-027 广东永顺生物制药股份有限公司拟续聘会计师事务所公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 涉及会计师事务所提供的资料、信息，会计师事务所保证其提供、报送或披 露的资料、信息真实、准确、完整，不得有虚假记载、误导性陈述或者重大遗漏。 一、拟续聘会计师事务所的基本情况 （一）机构信息 公司拟聘任天健会计师事务所（特殊普通合伙）为 2023 年年度的审计机构。 1.基本信息 会计师事务所名称：天健会计师事务所（特殊普通合伙） 成立日期：2011 年 7 月 18 日 组织形式：特殊普通合伙 注册地址：浙江省杭州市西湖区西溪路 128 号 6 楼 首席合伙人：胡少先 2022 年度末合伙人数量：225 人 2022 年度末签署过证券服务业务审计报告的注册会计师人数：780 人 2021 年收入总额（经审计）：350,100 万元 2021 年审计业务收入（经审计）：317,800 万元 2021 年证券业务收入（经审计）：190, ...

Financial Performance - The company's operating revenue for 2022 was CNY 348,717,555.84, a decrease of 4.07% compared to CNY 363,525,642.57 in 2021[27]. - The net profit attributable to shareholders for 2022 was CNY 86,035,881.94, down 5.81% from CNY 91,342,217.51 in 2021[27]. - The total assets at the end of 2022 amounted to CNY 868,912,246.16, reflecting a growth of 7.38% from CNY 809,181,608.59 at the end of 2021[28]. - The total liabilities increased by 66.45% to CNY 172,771,172.59 in 2022, compared to CNY 103,796,628.70 in 2021[28]. - The company's cash flow from operating activities for 2022 was CNY 69,106,539.37, a decline of 31.38% from CNY 100,703,991.33 in 2021[30]. - The gross profit margin for 2022 was 62.53%, down from 67.43% in 2021[27]. - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 12.38% for 2022, compared to 13.32% in 2021[27]. - The company reported a basic earnings per share of CNY 0.32 for 2022, a decrease of 3.03% from CNY 0.33 in 2021[27]. - The company reported a total non-recurring profit and loss of ¥10,954,801.97 in 2022, an increase of 55.5% compared to ¥7,074,154.63 in 2021[36]. - The company distributed cash dividends totaling 76.36 million yuan based on a plan to distribute 2.8 yuan per 10 shares[55]. Research and Development - The company holds 24 invention patents and 9 utility model patents, with 19 new veterinary drug certificates obtained[12]. - The company has developed two new veterinary vaccines, but market acceptance is currently low, leading to potential revenue risks[13]. - Research and development expenses amounted to 25.38 million yuan, representing 7.28% of operating revenue, with new veterinary drug certificates and patents obtained during the period[51]. - The company is developing a new multi-valent inactivated vaccine for poultry, aiming to enhance immune protection efficiency and product practicality, with the goal of obtaining new veterinary drug certificates and achieving industrialization[100]. - The company is working on a new bivalent inactivated vaccine for swine influenza (H1N1 and H3N2), utilizing MDCK cell culture, which is expected to contribute positively to the development of swine influenza vaccines[100]. - The company is developing a heat-resistant inactivated vaccine for swine diseases, which aims to simplify immunization procedures and reduce stress and infection risks, thereby improving immune efficacy[100]. - The company is advancing the development of a carbon nanotube-based subunit vaccine for the bass virus, addressing urgent needs in the aquaculture industry and aiming for industrialization[100]. - The company is establishing a gene editing technology and recombinant protein expression techniques to create safer and more effective vaccines against major animal diseases[102]. - The company is focusing on the development of multi-valent vaccines to optimize immunization programs and reduce costs for livestock farmers[117]. Market and Industry Risks - The company faces risks related to fluctuations in the downstream livestock and poultry farming industry, which could impact vaccine demand and overall performance[11]. - The company’s main products include high pathogenic avian influenza vaccines, which are subject to national procurement policy changes[11]. - The company faces risks related to the sustainability of cooperative research and technology introduction partnerships[13]. - The company has implemented effective measures to mitigate environmental impact, but risks remain if compliance with environmental standards is not maintained[13]. - The company’s product demand is closely tied to the livestock industry, with potential performance fluctuations due to natural disasters or major animal disease outbreaks[127]. - The company is a designated producer of inactivated avian influenza vaccines, and changes in national procurement policies could adversely affect profitability[128]. Corporate Governance and Compliance - The company has a total share capital of 273,350,000 shares, with 80,244,567 shares (29.36%) being unrestricted and 193,105,433 shares (70.64%) being restricted[174]. - The board of directors consists of 9 members, with no controlling shareholder or actual controller present[199]. - The company has a supervisory board consisting of 3 members[198]. - The company has a total of 3 independent directors, ensuring governance and oversight[198]. - The company has not reported any significant legal disputes or conflicts of interest involving its directors and senior management during the reporting period[162]. - The commitments made by the company and its major shareholders regarding the avoidance of related party transactions are being fulfilled[159]. - The company has confirmed that all commitments made prior to its listing on the New Third Board are being actively fulfilled[154]. Environmental and Social Responsibility - The company reported a wastewater discharge of 61,627.03 tons per year, with treatment systems in place to manage this waste[116]. - The company donated RMB 36,000 worth of epidemic prevention supplies to the authorities in Yanbian, Jilin Province, during the reporting period[115]. - The company has implemented strict biosecurity measures and management systems to mitigate the risk of biological safety incidents during vaccine production[132]. - Environmental protection measures are in place to comply with regulations, but failure to adhere to increasing standards could lead to operational and reputational damage[141]. Shareholder Information - The top three shareholders of Guangdong Yongshun Biological Pharmaceutical Co., Ltd. are Modern Agricultural Group (39.0638%), Guangdong Agricultural Asset Management Co., Ltd. (19.7081%), and the Animal Health Research Institute of the Guangdong Academy of Agricultural Sciences (11.2676%)[181]. - The total number of shares held by the top ten shareholders is 221,714,894, representing 81.1103% of the total shares[178]. - The company has a total of 3,640 common shareholders, indicating a diverse shareholder base[174]. - The company has ongoing commitments from major shareholders to avoid related party transactions and fund occupation, which are currently being fulfilled[153]. Financial Management - The company has secured loans totaling CNY 20,000,000.00 from China Construction Bank at an interest rate of 3% and CNY 9,900,000.00 from Agricultural Bank of China at the same interest rate[192]. - The company has applied for commercial acceptance bill discount financing totaling CNY 62,313,700.00, with an outstanding balance of CNY 27,542,200.00 as of the reporting period end[193]. - The company has complied with regulatory requirements regarding the management and use of raised funds, with no violations reported[188]. - The company has not changed the intended use of the raised funds, and all funds have been used as planned[189].

证券代码：839729 证券简称：永顺生物 公告编号：2023-029 广东永顺生物制药股份有限公司董事任命公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、任免基本情况 （一）任免的基本情况 根据《公司法》及《公司章程》等有关规定，2023 年 4 月 19 日公司第四届董事会 第十三次会议审议并通过《关于补选公司第四届董事会非独立董事的议案》、《关于补选 公司第四届董事会独立董事的议案》。 提名张建峰先生为公司董事，任职期限自股东大会审议通过之日起至第四届董事会 任期届满为止，本次任免尚需提交股东大会审议，自 2022 年年度股东大会决议通过之 日起生效。上述提名人员持有公司股份 0 股，占公司股本的 0%，不是失信联合惩戒对 象。 提名任涛先生为公司独立董事，任职期限自股东大会审议通过之日起至第四届董事 会任期届满为止，本次任免尚需提交股东大会审议，自 2022 年年度股东大会决议通过 之日起生效。上述提名人员持有公司股份 0 股，占公司股本的 0%，不是失信联合惩戒 对象。 （二）任命原因 ...